Finance

1inch Announces Fusion+ Upgrade, Enabling Secure, Decentralized Cross-Chain Swaps for Web3 Users

Dubai, UAE, September 18th, 2024, FinanceWire

1inch is thrilled to unveil Fusion+, bringing users cross-chain functionality in an upgrade of the intent-based swap product. With Fusion+, users can retain full self-custody of their assets, while the architecture ensures transactions are fully completed on the two networks involved in the swap, without relying on third parties.

1inch, a decentralized finance (DeFi) project, has introduced Fusion+, an upgrade designed to enhance cross-chain swaps by integrating liquidity from across the Web3 ecosystem. The introduction of 1inch Fusion brings together on- and off-chain liquidity using an intent-based approach to deliver convenient and secure swaps designed with built-in MEV protection.

While historically, cross-chain swaps were hindered by slow, costly bridges and risks of centralized exchanges, Fusion+ aims to address these challenges by offering a decentralized, self-custodial solution that taps into the vast liquidity of Web3, ensuring users get the best rates with unmatched security.

Fusion+ is a true cross-chain gamechanger. This upgrade integrates liquidity from the entire Web3 ecosystem, enabling fast, efficient and secure cross-chain swaps – all from a single platform. The cross-chain swap upgrade builds on the intent-based approach introduced with the launch of 1inch Fusion in late 2022, as well as groundbreaking atomic swap technology.

The 1inch Fusion swaps works as follows: users specify the minimum return they’re willing to accept, and professional traders, known as resolvers, compete to execute swaps at the most favorable rates. The pricing is determined through a Dutch auction model, where Fusion swaps’ filling rates decrease over time, influenced by swap volume and user-established presets, which define price and duration limits. A smart price curve accounts for market liquidity and adjusts based on gas prices to ensure optimal execution for users.

The Benefits of Atomic Swap Technology

Fusion+ integrates atomic swap technology, ensuring that cross-chain swaps are:

  • Secure: “atomic” swaps are designed to be all-or-nothing transactions. If a swap fails to complete for any reason (such as timelock expiration), the assets are safely returned to the original owner.
  • Trustless: both parties can exchange assets without the need for mutual trust, as the swap is governed by smart contracts. These contracts verify all conditions of the transaction, meaning no one needs to trust each other or a third party to make the swap happen.

The key takeaway is that the process is entirely trustless, functioning purely through verification. This critical aspect of verification is also applied in Fusion+ cross-chain swaps, which is why users must keep the Swap tab in the dApp or application (when available in the 1inch Wallet) open until the swap is fully verified, ensuring the highest level of safety.

Currently, Fusion+ is in its beta version, and users who wish to try cross-chain swaps need to manually enable Fusion+ in Settings. After the testing period, Fusion+ cross-chain swaps will be automatically enabled.

Behind the scenes: the mechanics of Fusion+

The process works as follows: For example, a user holds POL tokens on Polygon and wants to swap them for ETH on Ethereum.

  • Initiating the swap: a user enters order details in the swap form, and the order is shared with resolvers. A Dutch auction begins, where the price decreases until a resolver accepts the order.
  • Locking the funds: the resolver deposits the user’s POL tokens into an escrow contract on Polygon by executing the 1inch Fusion order. The escrow contract includes the secret hash, token details and a timelock. Simultaneously, the resolver deposits ETH into an escrow on Ethereum, using the same secret and conditions.
  • Completing the swap: once both contracts are active on-chain, the cryptographic secret is revealed. The resolver unlocks ETH to the user on Ethereum and claims the POL tokens on Polygon, finalizing the exchange.

  • Timelock protection: if the swap is not completed within the designated time, the resolver cancels the contracts, and the funds are returned to their original owners.

Fusion+ now live in the 1inch dApp, coming soon to the 1inch Wallet

Users can experience seamless Fusion+ cross-chain swaps in the 1inch dApp. To be among the first to leverage these benefits, users can enable Fusion+ in Settings. With Fusion+, 1inch is setting a new cross-chain standard while advancing the security and decentralization of the Web3 space.

About 1inch

1inch is a leading DeFi project empowering Web3 users with innovative blockchain products and solutions. Launched in 2019 at a hackathon in New York City, 1inch offers users and developers the most secure, reliable, and efficient tools for growing and expanding the Web3 space.

Currently, 1inch Swap is a top DEX aggregator on the market, facilitating cost-efficient and secure crypto swaps across multiple liquidity sources. The 1inch Wallet is one of the most user-friendly and secure Web3 wallets, and the 1inch Portfolio is highly regarded as one of the most efficient DeFi trackers, providing accurate analytics on the market for numerous DeFi protocols. In line with its active involvement in the community, in 2023, 1inch launched the Developer Portal, offering an extensive suite of Web3 tools and services. For more information, readers can visit https://1inch.io.

Contact

PR lead
Pavel Kruglov
1inch Labs
p.kruglov@1inch.io

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection

2024-09-17T13:00:00Z

Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform

AMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube’s advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which RenovaroCube is based.

Prof. Mark Hoogendoorn, also a professor of Artificial Intelligence, expressed his enthusiasm: “We were pleased to be engaged to make an assessment of the AI platform; this is exactly the area of PersonalAIze’s expertise.”

Frank van Asch remarked on the collaboration, “The expertise of PersonalAIze’s team is exceptional, and their positive evaluation of our AI/ML platform is invaluable.”

RenovaroCube's AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.

The initial aim is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.

In their analysis, PersonalAIze noted the platform's focus on liquid biopsies and third-generation sequencing coupled with AI techniques as highly promising, potentially allowing for comprehensive analysis across varying cancer types and stages. Prof. Sandjai Bhulai, also a professor of Mathematics, commented on the platform’s unique potential and the impressive multidisciplinary team at RenovaroCube under Frank van Asch’s leadership.

Based on these findings, PersonalAIze is eager to collaborate further with RenovaroCube to enhance and commercialize the platform.

PersonalAIze aims to contribute in several key areas:

  • Advancing AI models by leveraging the latest state-of-the-art techniques.
  • Supporting the professional growth of the software team.
  • Enhancing the explainability of AI models, engaging clinicians in model development.
  • Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.

This partnership could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.

About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

About PersonalAIze
PersonalAIze focusses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision making systems as well as improvement of health care operations such as capacity planning.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.


GlobeNewsWire News

Recent Comments